- Conditions
- Corneal Toxicity, Ototoxicity, Surgical Site Infection
- Interventions
- Not listed
- Lead sponsor
- Mayo Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 600 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2013
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Bone Marrow Suppression, Brain and Central Nervous System Tumors, Drug/Agent Toxicity by Tissue/Organ
- Interventions
- filgrastim, gene therapy, lomustine, procarbazine hydrochloride, vincristine sulfate, in vitro-treated peripheral blood stem cell transplantation
- Procedure · Biological · Drug
- Lead sponsor
- Indiana University
- Other
- Eligibility
- 5 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2011
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Boston, Massachusetts
- Conditions
- Gastroparesis
- Interventions
- Erythromycin, Azithromycin
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Cardiotoxicity, Lung Cancer Stage III, Lung Cancer Stage II, Radiation Toxicity
- Interventions
- Chemoradiation
- Other
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Boston, Massachusetts • St Louis, Missouri + 5 more
- Conditions
- Schizophrenia, Bipolar Disorder, Autistic Disorder, Conduct and Other Disruptive Behavior Disorders
- Interventions
- Risperidone, Other atypical antipsychotic drugs
- Drug
- Lead sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Industry
- Eligibility
- 8 Years to 16 Years
- Enrollment
- 244 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 13
- States / cities
- San Francisco, California • Aurora, Colorado • Altamonte Springs, Florida + 10 more
- Conditions
- Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
- Interventions
- Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
- Drug
- Lead sponsor
- Mundipharma Research Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 71 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more
- Conditions
- Adverse Drug Events (ADEs)
- Interventions
- SBAR
- Other
- Lead sponsor
- University of Massachusetts, Worcester
- Other
- Eligibility
- Not listed
- Enrollment
- 26 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2009
- U.S. locations
- 2
- States / cities
- Middletown, Connecticut • Worcester, Massachusetts
- Conditions
- Childhood Germ Cell Tumor, Drug/Agent Toxicity by Tissue/Organ, Extragonadal Germ Cell Tumor, Ovarian Cancer
- Interventions
- bleomycin sulfate, amifostine trihydrate, cisplatin, etoposide, conventional surgery
- Biological · Drug · Procedure
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- Up to 14 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2007
- U.S. locations
- 97
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Tucson, Arizona + 74 more
- Conditions
- Drug/Agent Toxicity by Tissue/Organ, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Oral Complications, Radiation Toxicity
- Interventions
- filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, quality-of-life assessment, radiation therapy
- Biological · Drug · Procedure + 1 more
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Other
- Eligibility
- 12 Years to 65 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2004
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Parkinson's Disease, Dyskinesia
- Interventions
- Not listed
- Lead sponsor
- Great Lakes NeuroTechnologies Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2011
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Multiple Myeloma, Shortness of Breath, Dyspnea, Cardiotoxicity
- Interventions
- EndoPAT, Blood Pressure Cuff, Echocardiogram, Quality of Life Assessment, Blood Tests
- Device · Diagnostic Test · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Urinary Tract Infections
- Interventions
- Not listed
- Lead sponsor
- Pathnostics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,308 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Louisville, Kentucky • Royal Oak, Michigan
- Conditions
- Breast Cancer, Cardiac Toxicity
- Interventions
- management of therapy complications
- Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years to 120 Years · Female only
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1997
- U.S. locations
- 105
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 67 more
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Skin Cancer Stage III, Skin Cancer Stage IV, Drug-Induced Colitis, Drug Toxicity, Immune-related Adverse Event
- Interventions
- Infliximab, Methylprednisolone, Prednisone
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts
- Conditions
- Aspirin Exacerbated Respiratory Disease (AERD)
- Interventions
- Ifetroban, Oral Capsule, Placebo, Oral Capsule
- Drug
- Lead sponsor
- Cumberland Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 3
- States / cities
- San Diego, California • Overland Park, Kansas • West Nyack, New York
- Conditions
- Dry Eye Syndrome, Systemic Lupus Erythematosus
- Interventions
- ABBV-319
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 7
- States / cities
- Avon Park, Florida • Clearwater, Florida • Margate, Florida + 4 more
- Conditions
- Stevens-Johnson Syndrome, Toxic Epidermal Necrolyses
- Interventions
- Harmonized supportive care, Etanercept 50 mg sc day 1 and day 4
- Drug
- Lead sponsor
- Vanderbilt University Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Sacramento, California • Washington D.C., District of Columbia + 11 more
- Conditions
- Carcinoid Syndrome
- Interventions
- Lanreotide, Placebo
- Drug
- Lead sponsor
- Ipsen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2015
- U.S. locations
- 16
- States / cities
- Los Angeles, California • Stanford, California • West Hollywood, California + 11 more
- Conditions
- Asthma, Aspirin-induced
- Interventions
- Not listed
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2022
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
- Interventions
- Not listed
- Lead sponsor
- Genelex Corporation
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 7
- States / cities
- Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin frozen liquid, Belantamab mafodotin lyophilized powder
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 221 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 21
- States / cities
- New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 15 more
- Conditions
- Weight Gain, Disorder of Bone Density and Structure, Unspecified, Uterine Bleeding
- Interventions
- Depot medroxyprogesterone acetate (DMPA)
- Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 12 Years to 21 Years · Female only
- Enrollment
- 34 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Columbus, Ohio
- Conditions
- Toxic Epidermal Necrolysis
- Interventions
- Clobetasol 0.05% ointment, Placebo
- Drug
- Lead sponsor
- University of California, Davis
- Other
- Eligibility
- 7 Years to 85 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Hand Foot Syndrome, Palmar Plantar Erythrodysesthesia
- Interventions
- sildenafil citrate
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina